skip to Main Content

Immuno-PET/CT imaging with 89Zr-Rituximab as a prelude for radioimmunotherapy with 90Y-Rituximab in patients with relapsed CD20+ B-Cell non-Hodgkin’s lymphoma.

Back To Top